In an interview with Applied Clinical Trials Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, provides advice to small biopharma companies looking to scale their clinical programs without ...

Palobiofarma Partners with Flex Databases for Advanced Pharmacovigilance ManagementFebruary 6, 2025Palobiofarma, a leading ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

The Global Coalition for Adaptive Research (GCAR) today announced that they are collaborating with Operational Medical ...

Independent research institute BioMed X has completed its oncology research project in partnership with Merck, the data from ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...

Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities ...

X4 expects its efforts will decrease annual spending by $30-35 million and believes it will have sufficient funds to support operations into the first half of 2026. Workforce reductions are expected ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy Peter Ronco, CEO, Emmes, discusses the number of ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...

A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

Federal agencies have removed web pages dedicated to DEI programs related to cancer research and other clinical research.